K M Kam
About
In The Last Decade
K M Kam
28 papers receiving 611 citations
Peers
Comparison fields: 5 of 65
- Infectious Diseases 414
- Epidemiology 368
- Surgery 112
- Molecular Medicine 95
- Molecular Biology 94
Countries citing papers authored by K M Kam
This map shows the geographic impact of K M Kam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K M Kam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K M Kam more than expected).
Fields of papers citing papers by K M Kam
This network shows the impact of papers produced by K M Kam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K M Kam. The network helps show where K M Kam may publish in the future.
Co-authorship network of co-authors of K M Kam
This figure shows the co-authorship network connecting the top 25 collaborators of K M Kam. A scholar is included among the top collaborators of K M Kam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K M Kam. K M Kam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 15 | |
| 4 | 2 | |
| 5 | 27 | |
| 6 | Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. | 33 |
| 7 | 22 | |
| 8 | Bulk acid-fast staining of sputum smears: time to end a taboo. | 2 |
| 9 | 41 | |
| 10 | 26 | |
| 11 | Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. | 37 |
| 12 | 89 | |
| 13 | Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. | 22 |
| 14 | 50 | |
| 15 | 39 | |
| 16 | 1 | |
| 17 | 5 | |
| 18 | 43 | |
| 19 | 16 | |
| 20 | 0 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.